Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

96.27USD
10:54am EDT
Change (% chg)

$-1.43 (-1.46%)
Prev Close
$97.70
Open
$97.55
Day's High
$98.68
Day's Low
$96.21
Volume
57,782
Avg. Vol
370,805
52-wk High
$153.80
52-wk Low
$49.20

Chart for

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.59
Market Cap(Mil.): $9,786.75
Shares Outstanding(Mil.): 100.17
Dividend: --
Yield (%): --

Financials

  ALNY.OQ Industry Sector
P/E (TTM): -- 200.91 33.50
EPS (TTM): -5.41 -- --
ROI: -32.93 -0.75 13.17
ROE: -36.54 -2.86 14.98

BRIEF-Alnylam Pharma Co, Agilent Technologies Entered Manufacturing Services Agreement Providing For Supply Of Patisiran Drug Substance By Agilent

* CO, AGILENT TECHNOLOGIES ENTERED MANUFACTURING SERVICES AGREEMENT PROVIDING FOR SUPPLY OF PATISIRAN DRUG SUBSTANCE BY AGILENT

Apr 03 2018

BRIEF-Silence Therapeutics Brings Patent Infringement Proceedings Against Alnylam's Patisiran Product

* SAYS BROUGHT PATENT INFRINGEMENT PROCEEDINGS IN PORTUGAL AGAINST ALNYLAM'S PATISIRAN PRODUCT Source text for Eikon: Further company coverage:

Apr 03 2018

Pfizer's rare heart disease drug succeeds in late-stage study

Pfizer Inc's experimental drug to treat a rare and fatal disease linked to heart failure reduced deaths and need for hospitalizations in a late-stage study.

Mar 29 2018

UPDATE 2-Pfizer's rare heart disease drug succeeds in late-stage study

* Brokerage Suntrust estimates sales of $130 mln of drug in 2022

Mar 29 2018

BRIEF-Alnylam Receives European Medicines Agency Prime Designation For Accelerated Assessment Of Lumasiran

* ALNYLAM RECEIVES EUROPEAN MEDICINES AGENCY PRIME DESIGNATION FOR ACCELERATED ASSESSMENT OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

Mar 26 2018

BRIEF-Regeneron, Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis

* REGENERON AND ALNYLAM PHARMACEUTICALS ANNOUNCE COLLABORATION TO DISCOVER NEW TREATMENTS FOR NONALCOHOLIC STEATOHEPATITIS (NASH)

Mar 21 2018

BRIEF-Alnylam Retains Global Rights To Lumasiran, Investigational RNAi Therapeutic For Treatment Of Primary Hyperoxaluria Type 1

* ALNYLAM RETAINS GLOBAL RIGHTS TO LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

Mar 12 2018

BRIEF-Alnylam Pharmaceuticals Q4 Non-Gaap Loss Per Share $1.20

* ALNYLAM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

Feb 08 2018

BRIEF-FDA Granted Alnylam's Request For Priority Review

* ALNYLAM ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRIORITY REVIEW STATUS FOR PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

Feb 01 2018

BRIEF-Alnylam Announces EMA Acceptance Of Marketing Authorisation Application For Patisiran

* ALNYLAM ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORISATION APPLICATION (MAA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

Jan 25 2018

Earnings vs. Estimates